Dr. Robert S. Alter, MD

Medicare patients and services

Medicare patients, 2024

800

Services billed

43,309

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 29 companies reported 145 payments worth $39,678 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New Jersey →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $113,366 in research payments for these studies, mostly to the institutions running them.

• A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIB…
  Merck Sharp & Dohme LLC
• A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01
  Merck Sharp & Dohme LLC
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
  Sumitomo Pharma America, Inc. · Completed · NCT05605964
• A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants wi…
  Merck Sharp & Dohme LLC
• A phase i dose escalation and expanded cohort study of PF06821497 in the treatment of adult patients with relapsedrefractory small cell lung cancer sclc castration resistant prostate cancer crpc and follicular lymphom…
  Pfizer Inc.
• A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
  Exelixis Inc.
• Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365
  Merck Sharp & Dohme LLC
• A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not …
  AstraZeneca Pharmaceuticals LP
• A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
  Astellas Pharma Global Development
• A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
  Pfizer Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Hackensack

• Noa Biran, M.D.
• Michele L. Donato, MD
• Tatyana A. Feldman, M.D.
• Sarvarinder K. Gill
• Andre H. Goy, MD
• Deena M. Graham, M.D.
• Martin E. Gutierrez, MD
• Harry D. Harper, MD